Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer
NCT05496491Recruiting
- Sponsor
- University Hospital of Larissa
- Start
- Aug 2022
- Primary completion
- Aug 2028
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of capecitabine, oxaliplatin, fluorouracil and folinic acid in rectal cancer (2 arms), sponsored by University Hospital of Larissa. Primary endpoint: Disease Free Survival. Started Aug 2022; status: recruiting.
02
Drugs
capecitabineoxaliplatinfluorouracilfolinic acid
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05496491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05496491.